Increased adoption of clinical whole-genome sequencing is advancing diagnostics for rare diseases, which affect 15 million American children SAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Illumina, Inc.
Study shows that rare variants captured by Illumina WGS with DRAGEN™ variant calling explain most of the "missing heritability" in complex human diseases and traits, including those related to blood ...
During the meeting, Steve Barnard, PhD, Illumina’s CTO will provide new details about the company’s constellation mapped read technology. He will be joined by Niall Lennon, PhD, chair and CSO of Broad ...
SAN DIEGO, Oct. 15, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that GeneDx, a leader in genetic testing for rare diseases, is piloting Illumina's emerging constellation mapped ...
Longstanding partners bring together end-to-end workflows and leading CRISPRPerturb-seq technologies setting a standard for single-cell studies and enabling a 5billion single-cell atlas ecosystem ...
Taiwan-based gene sequencing company Genomics BioSci & Tech has entered a strategic partnership with global sequencing leader Illumina to jointly promote gene sequencing and multi-omics technologies ...
Saliva can provide researchers with a source of high-quality human genomic DNA. Although blood is commonly employed for this purpose, saliva offers several advantages. It is more readily accessible, ...
Hosted on MSN
Mastering whole genome sequencing coverage planning
Whole genome sequencing (WGS) delivers deep insights into genetics, but its reliability depends on aligning coverage depth and uniformity with the study’s goals. Current research and practical guides ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results